SPATA22

Across TCGA pan-cancer cohorts, SPATA22 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SPATA22 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SPATA22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPATA22 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC are the cancer types where SPATA22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	1.000	0.337	.022	8	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SPATA22–UCEC (OS)

Open the UCEC breakdown →